Lisa M. Shandley
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lisa M. Shandley has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
Ann C. Mertens
Department of Pediatrics, Aflac Cancer and Blood Disorders Center Emory University School of Medicine Atlanta Georgia USA
6 shared publicationsJessica B. Spencer
Division of Reproductive Endocrinology and Infertility, Department of Gynecology and Obstetrics Emory University School of Medicine Atlanta Georgia USA
4 shared publications- Penelope P. Howards
Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA
4 shared publications Lauren M. Kipling
Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia
3 shared publications- Amy Fothergill
Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia
2 shared publications - Heather S. Hipp
Division of Reproductive Endocrinology and Infertility, Department of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, Georgia, USA
2 shared publications
Latest Publications
- 6 June 2024
- Published by Wiley in British Journal of Haematology
- Vol. 205 (2) , 674-685
The impact of sickle cell disease and its treatment on ovarian reserve in reproductive‐aged Black women
Summary: We compared serum anti‐Mullerian hormone (AMH) levels in women with sickle cell disease (SCD) (n = 152) to those of Black comparison women (n = 128) between the ages of 20 and 45 years and evaluated the impact of hydroxyurea (HU) and iron overload on ovarian reserve in those with SCD. SCD treatment was abstracted from medical records. Linear regression models were fit to examine the relationship between log(AMH) and SCD, adjusting for age. The analysis was repeated to account for HU use (current, previous, never) and iron overload (ferritin ≥1000 ng/mL vs. <1000 ng/mL). AMH estimates among women with SCD were lower than those among comparison women (2.23, 95% confidence interval [CI] 1.80–2.76 vs. 4.12, 95% CI 3.11–5.45, respectively). Women with SCD who were currently using HU had 63% lower (95% CI 43–76) AMH values than comparison women; those with SCD with prior or no HU use also had lower AMH estimates than comparison women, but the difference was less pronounced. There were no differences in predicted AMH values among women with SCD for those with and without iron overload. Women with SCD and low AMH may have a shorter reproductive window and may benefit from referral to a reproductive specialist.
- 6 June 2024
- Published by Wiley in British Journal of Haematology
- Vol. 205 (2) , 674-685
The impact of sickle cell disease and its treatment on ovarian reserve in reproductive‐aged Black women
Summary: We compared serum anti‐Mullerian hormone (AMH) levels in women with sickle cell disease (SCD) (n = 152) to those of Black comparison women (n = 128) between the ages of 20 and 45 years and evaluated the impact of hydroxyurea (HU) and iron overload on ovarian reserve in those with SCD. SCD treatment was abstracted from medical records. Linear regression models were fit to examine the relationship between log(AMH) and SCD, adjusting for age. The analysis was repeated to account for HU use (current, previous, never) and iron overload (ferritin ≥1000 ng/mL vs. <1000 ng/mL). AMH estimates among women with SCD were lower than those among comparison women (2.23, 95% confidence interval [CI] 1.80–2.76 vs. 4.12, 95% CI 3.11–5.45, respectively). Women with SCD who were currently using HU had 63% lower (95% CI 43–76) AMH values than comparison women; those with SCD with prior or no HU use also had lower AMH estimates than comparison women, but the difference was less pronounced. There were no differences in predicted AMH values among women with SCD for those with and without iron overload. Women with SCD and low AMH may have a shorter reproductive window and may benefit from referral to a reproductive specialist.
- 14 December 2023
- Published by Elsevier in Fertility and Sterility
- Vol. 121 (4) , 578-588
The use of fertility treatments among reproductive-aged women after cancer
- 14 December 2023
- Published by Elsevier in Fertility and Sterility
- Vol. 121 (4) , 578-588
The use of fertility treatments among reproductive-aged women after cancer
- Open Access
- 7 November 2023
- Published by American Medical Association (AMA) in JAMA
- Vol. 330 (17) , 1691-1694
Trends and Outcomes of Assisted Reproductive Technology Cycles Using a Gestational Carrier Between 2014 and 2020
A gestational carrier is someone who carries a pregnancy on behalf of the intended parents after implantation of an embryo created using gametes originating from the intended parents or a third party.1 Use of gestational carriers has increased, likely due to increased visibility; wider availability of assisted reproductive technology services for lesbian, gay, bisexual, transgender, and queer patients2; and evolving laws regarding surrogacy.3
- 7 November 2023
- Published by American Medical Association (AMA) in JAMA
- Vol. 330 (17) , 1691-1694
Open AccessTrends and Outcomes of Assisted Reproductive Technology Cycles Using a Gestational Carrier Between 2014 and 2020
A gestational carrier is someone who carries a pregnancy on behalf of the intended parents after implantation of an embryo created using gametes originating from the intended parents or a third party.1 Use of gestational carriers has increased, likely due to increased visibility; wider availability of assisted reproductive technology services for lesbian, gay, bisexual, transgender, and queer patients2; and evolving laws regarding surrogacy.3
- Open Access
- 3 July 2023
- Published by Elsevier in Fertility and Sterility
- Vol. 120 (1) , e10
INTERNATIONAL GESTATIONAL SURROGACY IN THE UNITED STATES, 2014–2020
- 3 July 2023
- Published by Elsevier in Fertility and Sterility
- Vol. 120 (1) , e10
Open AccessINTERNATIONAL GESTATIONAL SURROGACY IN THE UNITED STATES, 2014–2020
- 1 May 2023
- Published by SAGE Publications in Journal of Women's Health
- Vol. 32 (5) , 574-582
The Risk of Infertility After Surgery for Benign Ovarian Cysts
Background: There is a growing body of evidence that ovarian cystectomy may negatively impact ovarian reserve. However, it is unclear whether ovarian cyst surgery puts women at risk of future infer...
- 1 May 2023
- Published by SAGE Publications in Journal of Women's Health
- Vol. 32 (5) , 574-582
The Risk of Infertility After Surgery for Benign Ovarian Cysts
Background: There is a growing body of evidence that ovarian cystectomy may negatively impact ovarian reserve. However, it is unclear whether ovarian cyst surgery puts women at risk of future infer...
- 16 May 2022
- Published by SAGE Publications in Journal of Women's Health
- Vol. 31 (5) , 665-674
Factors Associated with Unplanned Pregnancy Among Cancer Survivors
Background: Approximately half of all pregnancies in the United States are unintended. However, women who are diagnosed with cancer in their reproductive years may be a unique population. This study examines the prevalence of and identifies factors associated with unplanned pregnancy among cancer survivors. Materials and Methods: Female cancer survivors aged 22–45 years, diagnosed between ages 20–35 years and at least 2 years postdiagnosis, and women with no history of cancer were interviewed about their reproductive histories, including pregnancy intention. Using a random matching process, comparison women were assigned an artificial age at cancer diagnosis equal to that of her cancer survivor match. An adjusted Cox model was fit examining time to unintended pregnancy after cancer for each of 1,000 matches. Cox proportional hazards models were also fit to assess associations between participant characteristics and unplanned pregnancy after cancer among survivors. Results: Cancer survivors ( n = 1,282) and comparison women ( n = 1,073) reported a similar likelihood of having an unplanned pregnancy in models adjusted for race, income, history of sexually-transmitted infection, and history of unplanned pregnancy before diagnosis (adjusted hazard ratio [aHR] 1.06, 95% simulation interval 0.85–1.36). After adjusting for confounders, unplanned pregnancy among survivors was associated with age <30 years at diagnosis (hazard ratio [HR]: 1.79, 95% confidence interval [CI]: 1.32–2.44), black race (HR: 1.55, 95% CI: 1.13–2.12; referent: white), receiving fertility counseling (aHR: 1.41, 95% CI: 1.04–1.92), and having at least one child before diagnosis (aHR: 1.44, 95% CI: 1.05–1.97). Conclusion: Cancer survivors and comparison women had similar likelihood of unplanned pregnancy. Rates of unplanned pregnancy after cancer were not higher for cancer survivors compared with comparison women, but 46.4% of survivors with a postcancer pregnancy reported an unplanned pregnancy. Cancer patients may benefit from patient-centered guidelines and counseling before cancer treatment that covers both risks of infertility and risks of unplanned pregnancy.
- 16 May 2022
- Published by SAGE Publications in Journal of Women's Health
- Vol. 31 (5) , 665-674
Factors Associated with Unplanned Pregnancy Among Cancer Survivors
Background: Approximately half of all pregnancies in the United States are unintended. However, women who are diagnosed with cancer in their reproductive years may be a unique population. This study examines the prevalence of and identifies factors associated with unplanned pregnancy among cancer survivors. Materials and Methods: Female cancer survivors aged 22–45 years, diagnosed between ages 20–35 years and at least 2 years postdiagnosis, and women with no history of cancer were interviewed about their reproductive histories, including pregnancy intention. Using a random matching process, comparison women were assigned an artificial age at cancer diagnosis equal to that of her cancer survivor match. An adjusted Cox model was fit examining time to unintended pregnancy after cancer for each of 1,000 matches. Cox proportional hazards models were also fit to assess associations between participant characteristics and unplanned pregnancy after cancer among survivors. Results: Cancer survivors ( n = 1,282) and comparison women ( n = 1,073) reported a similar likelihood of having an unplanned pregnancy in models adjusted for race, income, history of sexually-transmitted infection, and history of unplanned pregnancy before diagnosis (adjusted hazard ratio [aHR] 1.06, 95% simulation interval 0.85–1.36). After adjusting for confounders, unplanned pregnancy among survivors was associated with age <30 years at diagnosis (hazard ratio [HR]: 1.79, 95% confidence interval [CI]: 1.32–2.44), black race (HR: 1.55, 95% CI: 1.13–2.12; referent: white), receiving fertility counseling (aHR: 1.41, 95% CI: 1.04–1.92), and having at least one child before diagnosis (aHR: 1.44, 95% CI: 1.05–1.97). Conclusion: Cancer survivors and comparison women had similar likelihood of unplanned pregnancy. Rates of unplanned pregnancy after cancer were not higher for cancer survivors compared with comparison women, but 46.4% of survivors with a postcancer pregnancy reported an unplanned pregnancy. Cancer patients may benefit from patient-centered guidelines and counseling before cancer treatment that covers both risks of infertility and risks of unplanned pregnancy.
- 1 April 2020
- Published by Elsevier in Fertility and Sterility
- Vol. 113 (4) , 797-810
Patient-centered care: factors associated with reporting a positive experience at United States fertility clinics
- 1 April 2020
- Published by Elsevier in Fertility and Sterility
- Vol. 113 (4) , 797-810
Patient-centered care: factors associated with reporting a positive experience at United States fertility clinics
- 1 March 2018
- Published by Elsevier in Fertility and Sterility
- Vol. 109 (3) , 516-525.e1
Impact of cancer treatment on risk of infertility and diminished ovarian reserve in women with polycystic ovary syndrome
- 1 March 2018
- Published by Elsevier in Fertility and Sterility
- Vol. 109 (3) , 516-525.e1
Impact of cancer treatment on risk of infertility and diminished ovarian reserve in women with polycystic ovary syndrome
- 1 January 2017
- Published by Elsevier in Fertility and Sterility
- Vol. 107 (1) , 243-252.e5
Impact of tamoxifen therapy on fertility in breast cancer survivors
- 1 January 2017
- Published by Elsevier in Fertility and Sterility
- Vol. 107 (1) , 243-252.e5
Impact of tamoxifen therapy on fertility in breast cancer survivors